Home / Health / PMC Funds Breakthrough Cancer Drug
PMC Funds Breakthrough Cancer Drug
30 Jul
Summary
- PMC has raised over $1.125 billion for Dana-Farber research since 1980.
- A new drug, daraxonrasib, has doubled survival rates for late-stage pancreatic cancer.
- PMC funding enables Dana-Farber to attract top cancer doctors and scientists.
The Pan-Mass Challenge (PMC) has profoundly impacted cancer research, contributing over $1.125 billion to Dana-Farber Cancer Institute since 1980. As an eight-year rider and CEO of Dana-Farber, Dr. Ben Ebert highlights the PMC's critical role in funding vital research and attracting top scientific talent.
The PMC's flexible funding has been instrumental in fostering a collaborative environment at Dana-Farber. This has led to significant breakthroughs, such as a novel treatment for pancreatic cancer. This experimental drug, daraxonrasib, targets a key mutation and has more than doubled survival rates for patients in clinical trials, offering new hope.
Dr. Ebert emphasizes that 100% of rider-raised funds directly support cancer research. The emotional support and community fostered by the PMC also provide a significant boost to patients undergoing treatment. The collective effort of PMC participants drives innovation and improves care for those affected by cancer.
